Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,286 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Severe Acute Respiratory Syndrome Coronavirus 2 Receptor (Human Angiotensin-Converting Enzyme 2) Binding Inhibition Assay: A Rapid, High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation.
Plested JS, Zhu M, Cloney-Clark S, Massuda E, Patel U, Klindworth A, Massare MJ, Cai R, Fries L, Glenn G, Kalkeri R. Plested JS, et al. Among authors: cai r. Microorganisms. 2023 Feb 1;11(2):368. doi: 10.3390/microorganisms11020368. Microorganisms. 2023. PMID: 36838333 Free PMC article.
Induction of Cross-Reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-Cell Responses by a Recombinant Matrix-M-Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine.
Shinde V, Cai R, Plested J, Cho I, Fiske J, Pham X, Zhu M, Cloney-Clark S, Wang N, Zhou H, Zhou B, Patel N, Massare MJ, Fix A, Spindler M, Thomas DN, Smith G, Fries L, Glenn GM. Shinde V, et al. Among authors: cai r. Clin Infect Dis. 2021 Dec 6;73(11):e4278-e4287. doi: 10.1093/cid/ciaa1673. Clin Infect Dis. 2021. PMID: 33146720 Free PMC article. Clinical Trial.
Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial.
Shinde V, Cho I, Plested JS, Agrawal S, Fiske J, Cai R, Zhou H, Pham X, Zhu M, Cloney-Clark S, Wang N, Zhou B, Lewis M, Price-Abbott P, Patel N, Massare MJ, Smith G, Keech C, Fries L, Glenn GM. Shinde V, et al. Among authors: cai r. Lancet Infect Dis. 2022 Jan;22(1):73-84. doi: 10.1016/S1473-3099(21)00192-4. Epub 2021 Sep 23. Lancet Infect Dis. 2022. PMID: 34563277 Clinical Trial.
Altered IgG4 Antibody Response to Repeated mRNA versus Protein COVID Vaccines.
Kalkeri R, Zhu M, Cloney-Clark S, Plested JS, Parekh A, Gorinson D, Cai R, Mahato S, Ramanathan P, Aurelia LC, Selva KJ, Marchese AM, Fries L, Chung AW, Dunkle LM. Kalkeri R, et al. Among authors: cai r. medRxiv [Preprint]. 2024 Jan 18:2024.01.17.24301374. doi: 10.1101/2024.01.17.24301374. medRxiv. 2024. PMID: 38293205 Free PMC article. Updated. Preprint.
Altered IgG4 antibody response to repeated mRNA versus recombinant protein SARS-CoV-2 vaccines.
Kalkeri R, Zhu M, Cloney-Clark S, Plested JS, Parekh A, Gorinson D, Cai R, Mahato S, Ramanathan P, Aurelia LC, Selva KJ, Marchese AM, Fries L, Chung AW, Dunkle LM. Kalkeri R, et al. Among authors: cai r. J Infect. 2024 Mar;88(3):106119. doi: 10.1016/j.jinf.2024.106119. Epub 2024 Feb 13. J Infect. 2024. PMID: 38360356 Free article. No abstract available.
Immunogenicity and Safety of 3 Formulations of a Respiratory Syncytial Virus Candidate Vaccine in Nonpregnant Women: A Phase 2, Randomized Trial.
Schwarz TF, McPhee RA, Launay O, Leroux-Roels G, Talli J, Picciolato M, Gao F, Cai R, Nguyen TL, Dieussaert I, Miller JM, Schmidt AC. Schwarz TF, et al. Among authors: cai r. J Infect Dis. 2019 Oct 22;220(11):1816-1825. doi: 10.1093/infdis/jiz395. J Infect Dis. 2019. PMID: 31418022 Free PMC article. Clinical Trial.
2,286 results